technology
Patient Reports Symptom Improvement in Phase III Trial of Experimental Targeted Chemotherapy for Pancreatic Cancer
Hernando Salcedo, 83, experienced fewer side effects and regained energy after eight TAMP sessions delivered via RenovoRx's RenovoCath device at Miami Cancer Institute. Early TIGeR-PaC trial data showed trends toward better survival and 65% fewer adverse events. Enrollment is expected to complete in mid-2026 with final results in 2027.
May 14, 9:20 AM·3m read1 source
Fox NewsAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
An 83-year-old patient with locally advanced pancreatic cancer reported dramatic improvement in his daily life after switching from standard intravenous chemotherapy to a targeted delivery system in a Phase III clinical trial. Hernando Salcedo was diagnosed after presenting with a swollen stomach and hip pain.
He began standard chemotherapy and radiation in August 2015 and experienced severe side effects including nausea, exhaustion, inflamed stomach, persistent head pain, weight loss and almost no energy.
"My body was going through an incredible amount of stress," Hernando Salcedo said. " After enrolling in the trial at Miami Cancer Institute, Hernando Salcedo completed eight sessions of TAMP treatment, one every 15 days.
After switching to TAMP he stopped losing weight, regained appetite, improved color, gained energy and felt dramatically better. "The difference was tremendous," Hernando Salcedo said. " He was able to attend a family wedding and dance the entire night after TAMP treatment.
"That moment meant everything to me," he said. " RenovoRx is developing the Trans-Arterial Micro-Perfusion (TAMP) targeted drug-delivery system for chemotherapy. The RenovoRx platform uses the FDA-cleared RenovoCath device to deliver chemotherapy through a catheter placed in an artery near the tumor.
The RenovoCath catheter procedure is minimally invasive, performed in an outpatient setting without general anesthesia. A physician guides the catheter into position using X-ray imaging. Once in position, two small balloons on the catheter are inflated to isolate a targeted segment of artery adjacent to a tumor, after which the chemotherapy drug is infused between the balloons.
